ArticleMalaria journal2026
Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria among children 6-59 months in three sentinel sites of Sierra Leone, 2021-2022.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimalarial drug resistance leads to increased treatment failures, prolonged illness, and increased mortality. The World Health Organization (WHO) recommends malaria-endemic countries regularly (ideally biennially) assess the efficacy of commonly used antimalarials. An evaluation of Sierra Leone's first and second-line antimalarials assessed artemether-lumefantrine (AL) in three sentinel sites-Bo, Bombali, and Kenema-and artesunate-amodiaquine (ASAQ) in two sites-Bo and Bombali. Children 6 months to 5 years old with uncomplicated malaria were enrolled in the 28 day in vivo efficacy study using the WHO-recommended protocols. Genotyping at three markers (msp1, msp2 and the PolyA microsatellite) and match counting using the WHO 3/3 algorithm were used to distinguish recrudescence from new infection, PCR-uncorrected and corrected efficacy results were calculated, and molecular markers of antimalarial resistance were analyzed. Of 1777 children screened, 496 reached a study endpoint. Kaplan-Meier uncorrected efficacy for AL was 89.5% (95% CI 84-95%) in Bo, 96.1% (95% CI 92-100%) in Bombali, and 93.2% (95% CI 89-98%) in Kenema; for ASAQ, estimates were 92.0% (95% CI 86-98%) in Bo and 94.5% (95% CI 90-99%) in Bombali. PCR-corrected Kaplan-Meier efficacy was 100% in all AL arms, 100% for ASAQ in Bo, and 99.1% (95% CI 97-100%) for ASAQ in Bombali.New infections accounted for 72.7% (16/22) and 63.6% (7/11) of recurrent parasitemia in the AL and ASAQ arms, respectively. No validated or candidate Pfk13 mutations were detected, and while some Pfmdr1 and Pfcrt polymorphisms were observed, no clear pattern of association with treatment failure was evident. Therefore, our study provides evidence that AL and ASAQ remain efficacious for treatment of P. falciparum infection in Sierra Leone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.